Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab in High-risk Smoldering Multiple Myeloma
NCT01484275Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2012
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of siltuximab in smoldering multiple myeloma (SMM), sponsored by Janssen Pharmaceutical. Started Mar 2012; status: completed.
02
Drugs
siltuximab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT01484275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01484275.